A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Inclusion Criteria

• Subjects with type 2 diabetes, currently treated with insulin glargine or other intermediate- or long-acting insulin, with or without oral antidiabetic medications, but experiencing inadequate glycemic control and willing and capable of participating in a regimen of intensive insulin administration. A subject who has been on an intermediate- or long acting insulin for >/=6 months but /= 20kg/m2 and /=0.8 ng/mL (>/= 0.26 nmol/L)
• HbA1c between 7.0% and 10.5%, inclusive
• Use of oral or systemically injected glucocorticoids is generally not allowed within 3 months before randomization; inhaled, intra articular, and topical corticosteroids are allowed
• Hemoglobin /=10 g/dL for female subjects
• Creatinine clearance >60 mL/min (calculated using the Cockcroft Gault formula)
• Thyroid stimulating hormone level is normal or clinically euthyroid as demonstrated by further thyroid tests (e.g., T4, T3, thyroid-binding globulin)
• Female subjects of childbearing potential (i.e., not surgically sterile and/or not postmenopausal) must be practicing adequate contraception. Adequate contraception must be practiced for the duration of participation in the study including the 8 week Posttreatment Follow-up Period
• Able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor as per the protocol recommendations of self administration
• No major illness or debility that in the investigator's opinion prohibits the subject from actively participating in their diabetes management and completing the study
• Able and willing to provide written informed consent

Exclusion Criteria

• History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 3 years before Screening.
• History of treated diabetic gastroparesis
• Current ongoing symptomatic biliary disease or history of pancreatitis
• History of significant gastrointestinal surgery, including gastric bypass and banding, antrectomy, Roux en Y bypass, gastric vagotomy, small bowel resection, or surgeries thought to significantly affect upper gastrointestinal function
• Recent clinically significant cardiovascular and/or cerebrovascular disease including but not limited to the following:
• Previous history of stroke or transient ischemic attack within 1 month before Screening.
• Acute coronary syndrome, which includes the following:
• Documented MI within the 2 months before Screening and during the period up until receiving the first dose of study medication
• Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within the 2 months before Screening and during the period up until receiving the first dose of study medication
• Unstable angina not responsive to nitroglycerin within the 2 months before Screening and during the period up until receiving the first dose of study medication
• Unstable cardiac rhythm, however, as an example, controlled atrial fibrillation is allowed
• Current or history of heart failure (New York Heart Association class I to IV).
• Resting systolic pressure is >160 mm Hg and/or diastolic pressure >100 mm Hg.
• QTc interval (Fridericia) >470 ms confirmed by a central reader at Screening
• History of stroke or other central nervous system disorder that would negatively impact the subject's ability to participate in a program of intensive insulin management (eg, physically or mentally incapable of performing home blood glucose monitoring or administering and/or adjusting insulin dosage)
• Hemoglobinopathy that may affect determination of HbA1c
• History of human immunodeficiency virus infection
• History of total bilirubin >1.5 × ULN unless the subject has a previously known history of Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin 2.5 ×ULN
• Fasting triglyceride level >850 mg/dL at Screening or Week -1 (Visit 5).
• Acute symp